Page last updated: 2024-08-21

pyrazines and Amyloidosis

pyrazines has been researched along with Amyloidosis in 80 studies

Research

Studies (80)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (8.75)	29.6817
2010's	72 (90.00)	24.3611
2020's	1 (1.25)	2.80

Authors

Authors	Studies
Garrido, D; Riva, E	1
Adam, Z; Cermáková, Z; Hájek, R; Král, Z; Krejčí, M; Mayer, J; Navrátil, M; Pospíšilová, Y; Pour, L; Sandecká, V; Stork, M; Zahradová, L	1
Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V	1
Huang, XJ; Lu, J; Wang, H	1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S	1
Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Pinney, JH; Roussel, M; Sachchithanantham, S; Venner, CP; Wechalekar, AD	1
Abe, D; Amagai, M; Hosokawa, R; Murakami, K; Ohyama, M; Okamoto, S; Yokoyama, K	1
Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K	1
Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J	1
Chen, W; Chen, Z; Gong, D; Huang, X; Liu, Z; Wang, Q; Zeng, C; Zhang, H	1
Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A	1
Abildgaard, N; Godskesen, L; Kjeldsen, J; Krag, A	1
Bridoux, F; Comenzo, RL; Decaux, O; Gillmore, J; Hari, P; Hawkins, PN; Jaccard, A; Lavergne, D; Lazaro, E; Macro, M; Mercie, P; Mohty, D; Morel, P; Pellegrin, JL; Roussel, M; Venner, CP; Wechalekar, AD	1
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ	2
Asahina, M; Ikeda, S; Kuwabara, S; Sano, K; Shiojiri, T; Sugiyama, A; Takeda, Y	1
de Waal, TT; Gorter, MH; Tascilar, M	1
Basset, M; Foli, A; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Perlini, S; Vidus Rosin, M	1
Fujiwara, K; Higo, H; Inomata, T; Kameyama, N; Makimoto, G; Matsushita, M; Rai, K; Sato, K; Shibayama, T; Sunami, K; Watanabe, H	1
Merlini, G; Palladini, G	1
Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Kukreti, V; Merlini, G; Palladini, G; Pei, L; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA	1
Choi, JO; Jeon, ES; Kim, HJ; Kim, JS; Kim, K; Kim, SJ; Lee, GY; Lee, JE; Lee, JY; Lee, SY; Lim, SH; Min, JH	1
Gertz, MA	1
Hata, H; Hirata, S; Ide, K; Kawaguchi, T; Kikukawa, Y; Matsuno, N; Mitsuya, H; Miyakawa, T; Nakata, H; Nosaka, K; Okuno, Y; Yonemura, Y; Yuki, H	1
Dispenzieri, A	1
Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST	1
Benner, A; Bochtler, T; Goldschmidt, H; Granzow, M; Hegenbart, U; Ho, AD; Hose, D; Jauch, A; Kimmich, C; Kunz, C; Schönland, SO; Seckinger, A	1
Gotoh, Y; Ihara, K; Inomata, H; Kato, J; Koyama, R; Miyajima, N; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Yamauchi, N	1
Basset, M; Foli, A; Gillmore, J; Hawkins, P; Lachmann, H; Merlini, G; Milani, P; Palladini, G; Sachchithanantham, S; Wechalekar, AD	1
Bladé, J; Cibeira, MT	1
Dispenzieri, A; Warsame, R	1
Benner, A; Bochtler, T; Hegenbart, U; Kunz, C; Schönland, SO	1
Alonso-Pulpón, L; García-Pavía, P; Gómez-Bueno, M; Jaramillo, N; Krsnik, I; Mingo, S; Oteo, JF; Salas, C; Sayago, I; Segovia, J	1
Dimopoulos, MA; Kastritis, E; Rajkumar, SV	1
Cakana, A; Comenzo, RL; Elsayed, YA; Fermand, JP; Hegenbart, U; Liu, X; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; Vescio, RA	1
Bitter, M; Brunvand, MW	1
Mehta, AB; Shah, AD; Watts, AJ; Wechalekar, AD	1
Handa, H; Higeta, D; Hirato, J; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saito, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A	1
Li, J; Su, C; Wang, HH; Zeng, LJ; Zhao, Y	1
Dimopoulos, MA; Gillmore, JD; Hawkins, PN; Kastritis, E; Merlini, G; Palladini, G; Perfetti, V; Wechalekar, AD	1
Chaudhary, R; Ghose, A; Taj, A; Tariq, Z	1
Adam, Z; Germáková, Z; Hájek, R; Kovárová, L; Krejcí, M; Kren, L; Krivanová, A; Mardová, J; Mayer, J; Moulis, M; Nedbálková, M; Pour, L; Stepánková, S; Svobodová, I; Veselý, K; Zahradová, L	1
Drach, J; Lamm, W; Lang, A; Ludwig, H; Müldür, E; Schauer-Stalzer, B; Willenbacher, W; Zielinski, CC; Zojer, N	1
Hao, H; Hasegawa, S; Hirota, S; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H; Taniguchi, Y	1
Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S	1
Foli, A; Lavatelli, F; Merlini, G; Milani, P; Obici, L; Palladini, G; Russo, P	1
Farrell, K; Soutar, R; Stobo, DB	1
Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G	1
Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P	1
Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Liu, K; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA	1
Bahram, S; Béné, MC; Davi, F; Gribben, JG; Herbrecht, R; Jacob, F; Leblond, V; Merle-Béral, H; Nadaud, S; Perrot, A; Pionneau, C; Vallat, L	1
Henderson, RA; McGhee, CN; Patel, D; Pradhan, MA; Vincent, AL	1
Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA	1
Badelita, S; Coriu, D; Crisan, M; Dobrea, C; Dogaru, M; Ostroveanu, D; Talmaci, R	1
Abonour, R; Benson, MD; Kramer, G; Suvannasankha, A	1
Antolino, G; Bianchi, MP; De Biase, L; La Verde, G; Monarca, B; Moscetti, A; Porrini, R; Saltarelli, F	1
Andrea, NT; Quillen, K; Sanchorawala, V; Seldin, DC; Sloan, JM	1
Falk, RH	1
Benjamin, M; Gibbs, S	1
Bridoux, F; Delbes, S; Desport, E; Fermand, JP; Jaccard, A; Pourreau, F; Puyade, M; Sirac, C; Touchard, G	1
Andreesen, R; Grube, M; Hafner, C; Hart, C; Wurm, S	1
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Pinney, JH; Rannigan, L; Venner, CP; Wechalekar, AD; Whelan, CJ	1
Bello, N; Bergsagel, PL; Fonseca, R; Jimenez-Zepeda, VH; Mikhael, JR; Reeder, CB; Schuster, SR; Spong, J; Stewart, AK	1
Domján, G; Gadó, K	1
Dispenzieri, A; Gertz, MA	1
Morgan, G	1
Charliński, G; Jedrzejczak, WW; Wiater, E	1
Cheung, J; Cornell, IS; Yau, AH	1
Bockorny, B; Bockorny, M; Bona, R; Chakravarty, S; Schulman, P	1
Arbeille, B; Croué, A; Ifrah, N; Levaltier, X; Marchand, A; Martin, L	1
Suzuki, K	1
Bello, C; Comenzo, RL; Flombaum, C; Giralt, S; Hassoun, H; Hoover, E; Landau, H; Liu, J; Maurer, M; Riedel, E; Rosenzweig, MA	1
Chari, A; Pri-Chen, H	1
Barley, K; Chari, A; Jagannath, S; Osman, K	1
Giralt, S; Landau, H; Rosenzweig, M	1
Gertz, MA; Hayman, SR; Sher, T	1
Gatt, ME; Palladini, G	1
Merlini, G; Palladini, G; Sitia, R	1
Anagnostopoulos, A; Delibasi, S; Dimopoulos, MA; Kastritis, E; Mellou, S; Migkou, M; Nanas, J; Pamboukas, C; Psimenou, E; Roussou, M; Tassidou, A; Terpos, E; Toumanidis, S; Xilouri, I	1
Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD	1

Reviews

12 review(s) available for pyrazines and Amyloidosis

Article	Year
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:1 Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide	2013
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American journal of hematology, 2014, Volume: 89, Issue:12 Topics: Age Factors; Amyloidosis; Antineoplastic Agents; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Pyrazines; Stem Cell Transplantation; Subcutaneous Fat; Survival Analysis; Troponin T	2014
Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 2008, Volume: 22, Issue:7 Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia	2008
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis]. Vnitrni lekarstvi, 2010, Volume: 56, Issue:3 Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Thalidomide	2010
[Current treatment of AL amyloidosis]. Nephrologie & therapeutique, 2011, Volume: 7, Issue:6 Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide	2011
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress]. Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:3 Pt 1 Topics: Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Heart Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Kidney Transplantation; Melphalan; Paraproteinemias; Plasma Exchange; Pyrazines	2012
[AL amyloidosis]. Orvosi hetilap, 2012, Apr-15, Volume: 153, Issue:15 Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2012
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:2 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Prognosis; Pyrazines; Thalidomide	2012
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta haematologica, 2012, Volume: 128, Issue:4 Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Middle Aged; Multiple Myeloma; Myocarditis; Proteasome Inhibitors; Pyrazines	2012
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and experimental nephrology, 2012, Volume: 16, Issue:5 Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide	2012
Light-chain amyloidosis: SCT, novel agents and beyond. Bone marrow transplantation, 2013, Volume: 48, Issue:8 Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide	2013
Light chain amyloidosis 2012: a new era. British journal of haematology, 2013, Volume: 160, Issue:5 Topics: Alkylating Agents; Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Forecasting; Humans; Immunoglobulin Light Chains; Immunologic Factors; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrazines; Risk; Severity of Illness Index; Stem Cell Transplantation; Troponin C; Troponin T	2013

Trials

8 trial(s) available for pyrazines and Amyloidosis

Article	Year
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC medicine, 2014, Jan-06, Volume: 12 Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Rate; Transplantation, Autologous	2014
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood, 2014, Oct-16, Volume: 124, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis	2014
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 2009, Aug-20, Volume: 114, Issue:8 Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Treatment Outcome	2009
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 2011, Jul-28, Volume: 118, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence	2011
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:11 Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome	2011
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica, 2011, Volume: 96, Issue:12 Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous	2011
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia, 2013, Volume: 27, Issue:4 Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Pyrazines; Stem Cell Transplantation	2013
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 2007, Volume: 92, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome	2007

Other Studies

60 other study(ies) available for pyrazines and Amyloidosis

Article	Year
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:7 Topics: Acyclovir; Amyloidosis; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Encephalitis, Herpes Simplex; Herpesvirus 3, Human; Humans; Middle Aged; Multiple Myeloma; Pyrazines	2022
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens]. Vnitrni lekarstvi, 2012, Volume: 58, Issue:12 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Pyrazines	2012
[Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4 Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Retrospective Studies; Treatment Outcome	2013
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10 Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine	2013
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis. British journal of haematology, 2013, Volume: 162, Issue:6 Topics: Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin D; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome; Vincristine	2013
Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma. The Journal of dermatology, 2013, Volume: 40, Issue:9 Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Pyrazines	2013
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clinical therapeutics, 2013, Volume: 35, Issue:10 Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia	2013
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:5 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome	2013
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2014
A rare cause of severe hepatomegaly with an improving outcome. BMJ case reports, 2014, Apr-03, Volume: 2014 Topics: Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Hepatomegaly; Humans; Male; Multiple Myeloma; Pyrazines	2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica, 2014, Volume: 99, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protein Aggregates; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome	2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. British journal of haematology, 2014, Volume: 166, Issue:6 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome	2014
Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2014, Volume: 21, Issue:3 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Neural Conduction; Pure Autonomic Failure; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome	2014
[Gastrointestinal amyloidosis in a patient with multiple myeloma]. Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158 Topics: Abdominal Pain; Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Colon, Sigmoid; Dexamethasone; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines	2014
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia, 2014, Volume: 28, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome	2014
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia, 2014, Volume: 28, Issue:12 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Middle Aged; Pyrazines; Treatment Outcome	2014
Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:16 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome	2014
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need. Haematologica, 2014, Volume: 99, Issue:9 Topics: Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Pyrazines	2014
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2014, Volume: 21, Issue:4 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisolone; Pyrazines; Retrospective Studies	2014
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. International journal of hematology, 2015, Volume: 101, Issue:2 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Japan; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pyrazines; Retrospective Studies; Survival Analysis; Treatment Outcome	2015
Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis. Leukemia, 2014, Volume: 28, Issue:12 Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Treatment Outcome	2014
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. American journal of hematology, 2015, Volume: 90, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome	2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-20, Volume: 33, Issue:12 Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Translocation, Genetic; Treatment Outcome	2015
[Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:3 Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation, Autologous	2015
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, Jul-30, Volume: 126, Issue:5 Topics: Amyloid; Amyloidosis; Boronic Acids; Bortezomib; Cooperative Behavior; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Europe; Heart Diseases; Humans; Kidney Diseases; Pyrazines; Treatment Outcome	2015
Upfront CyBorD in AL amyloidosis. Blood, 2015, Jul-30, Volume: 126, Issue:5 Topics: Amyloidosis; Boronic Acids; Cyclophosphamide; Dexamethasone; Humans; Pyrazines	2015
Blaming the Right Fluorescent in Situ Hybridization. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-20, Volume: 33, Issue:33 Topics: Amyloidosis; Boronic Acids; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Dexamethasone; Female; Humans; Male; Pyrazines; Translocation, Genetic	2015
Reply to R. Warsame et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-20, Volume: 33, Issue:33 Topics: Amyloidosis; Boronic Acids; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Dexamethasone; Female; Humans; Male; Pyrazines; Translocation, Genetic	2015
Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2016, Volume: 35, Issue:8 Topics: Amyloidosis; Boronic Acids; Delayed Diagnosis; Humans; Pyrazines; Retrospective Studies	2016
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant. Haematologica, 2010, Volume: 95, Issue:3 Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Recurrence; Transplantation, Autologous	2010
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis. International journal of hematology, 2010, Volume: 91, Issue:1 Topics: Amyloidosis; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Paraproteinemias; Protease Inhibitors; Pyrazines	2010
[IgM-lambda multiple myeloma presenting with systemic amyloidosis]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:12 Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Vincristine	2009
[The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis]. Zhonghua nei ke za zhi, 2009, Volume: 48, Issue:9 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome	2009
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome	2010
Acute dyspnea from treatment of AL amyloidisis with bortezomib. American journal of therapeutics, 2011, Volume: 18, Issue:4 Topics: Acute Disease; Aged; Amyloidosis; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dyspnea; Humans; Kidney Diseases; Male; Middle Aged; Protease Inhibitors; Pyrazines	2011
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Annals of hematology, 2011, Volume: 90, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome	2011
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib. International journal of hematology, 2010, Volume: 92, Issue:4 Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Echocardiography; Heart Diseases; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Myocardium; Protease Inhibitors; Pyrazines; Stroke Volume; Treatment Outcome	2010
De novo AL amyloidosis in the kidney allograft. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011, Volume: 11, Issue:3 Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome	2011
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1 Topics: Aged; Amyloidosis; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin M; Lymphatic Diseases; Male; Middle Aged; Pyrazines; Rituximab	2011
Cervical amyloidoma successfully treated with bortezomib and dexamethasone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-10, Volume: 29, Issue:17 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cervical Vertebrae; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Pyrazines; Spinal Neoplasms	2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of hematology, 2012, Volume: 91, Issue:1 Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2012
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood, 2011, Jul-28, Volume: 118, Issue:4 Topics: Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Protease Inhibitors; Pyrazines	2011
Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy. Cornea, 2011, Volume: 30, Issue:10 Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Corneal Dystrophies, Hereditary; Dexamethasone; DNA Mutational Analysis; Extracellular Matrix Proteins; Gelsolin; Glucocorticoids; Humans; Immunoglobulin Heavy Chains; Male; Mass Spectrometry; Melphalan; Microscopy, Confocal; Middle Aged; Mutation; Nephrotic Syndrome; Paraproteinemias; Pyrazines; Sequence Analysis, Protein; Transforming Growth Factor beta	2011
Bortezomib in systemic AL amyloidosis: a single center experience. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines	2011
Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1 Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Indiana; Male; Middle Aged; Pyrazines	2011
Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Echocardiography; Female; Humans; Immunoglobulin Light Chains; Pyrazines; Recurrence	2011
Cardiac amyloidosis: a treatable disease, often overlooked. Circulation, 2011, Aug-30, Volume: 124, Issue:9 Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2011
Amyloidosis. BMJ (Clinical research ed.), 2011, Nov-16, Volume: 343 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Delayed Diagnosis; Dexamethasone; Dyspnea; Heart Diseases; Humans; Kidney; Kidney Diseases; Male; Narration; Pyrazines; Quality of Life; Serum Amyloid A Protein; Thalidomide	2011
[Unusual skin alterations in a 72-year-old patient with multiple myeloma]. Der Internist, 2012, Volume: 53, Issue:4 Topics: Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome	2012
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 2012, May-10, Volume: 119, Issue:19 Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clonal Evolution; Cohort Studies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome	2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 2012, May-10, Volume: 119, Issue:19 Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Humans; Kidney; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors	2012
Myeloma: diagnosis complications and supportive care. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid	2012
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190 Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide	2012
Jejunal amyloidosis: a rare cause of severe gastrointestinal bleeding. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:6 Topics: Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Biopsy; Blood Transfusion; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Glucocorticoids; Humans; Jejunal Diseases; Pyrazines	2012
Cutaneous amyloid elastosis revealing multiple myeloma with systemic amyloidosis. Acta dermato-venereologica, 2013, Mar-27, Volume: 93, Issue:2 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnostic Errors; Elastic Tissue; Fatal Outcome; Female; Humans; Melphalan; Multiple Myeloma; Predictive Value of Tests; Pseudoxanthoma Elasticum; Pyrazines; Skin; Treatment Outcome	2013
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosis. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:3 Topics: Amyloidosis; Boronic Acids; Bortezomib; Erectile Dysfunction; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines	2013
Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:1 Topics: Adult; Aged; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2013
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy. Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:10 Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, 2007, Volume: 92, Issue:10 Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Humans; Kidney; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome	2007
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica, 2008, Volume: 93, Issue:2 Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide	2008